Ladiratuzumab vedotin

Ladiratuzumab vedotin targets LIV-1 using our proprietary antibody–drug conjugate (ADC) technology. LIV-1 is expressed in most metastatic breast cancers, as well as in melanoma, and prostate, ovarian, uterine, and cervical cancers.1

Proposed mechanism of action

View Details
Seagen medication lidiratuzumab vedotin
Seagen medication lidiratuzumab vedotin annotated

Ladiratuzumab vedotin is an investigational agent. Its safety and efficacy have not yet been established.

References

+
  1. Sussman D, et al. (2014). SGN-LIV1A: a development stage antibody drug-conjugate targeting LIV-1 for the treatment of metastatic breast cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res. 2013;73(8 Suppl):Abstract nr 3962. doi:10.1158/1538-7445.AM2013-3962.